Cancers, Vol. 13, Pages 318: The Hippo Signaling Pathway in Drug Resistance in Cancer

Cancers, Vol. 13, Pages 318: The Hippo Signaling Pathway in Drug Resistance in Cancer Cancers doi: 10.3390/cancers13020318 Authors: Renya Zeng Jixin Dong Chemotherapy represents one of the most efficacious strategies to treat cancer patients, bringing advantageous changes at least temporarily even to those patients with incurable malignancies. However, most patients respond poorly after a certain number of cycles of treatment due to the development of drug resistance. Resistance to drugs administrated to cancer patients greatly limits the benefits that patients can achieve and continues to be a severe clinical difficulty. Among the mechanisms which have been uncovered to mediate anti-cancer drug resistance, the Hippo signaling pathway is gaining increasing attention due to the remarkable oncogenic activities of its components (for example, YAP and TAZ) and their druggable properties. This review will highlight current understanding of how the Hippo signaling pathway regulates anti-cancer drug resistance in tumor cells, and currently available pharmacological interventions targeting the Hippo pathway to eradicate malignant cells and potentially treat cancer patients.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research